Cooper Companies, INC.: management transactions · United States · SEC (Form 4)

About Cooper Companies, INC.

Cooper Companies, Inc. (ticker: COO) is a U.S.-listed medical technology group traded on the Nasdaq in the United States. For French-, Belgian- and Swiss-based investors, the company is best understood as a specialized healthcare platform with two complementary operating segments: CooperVision, focused on contact lenses and vision-care solutions, and CooperSurgical, focused on women’s health, fertility, and selected surgical and diagnostic devices. This combination gives the group exposure to structurally attractive end markets such as eye care, myopia management, reproductive health, and gynecology. ([coopercos.com](https://www.coopercos.com/our-company/?utm_source=openai)) The company has a long operating history in healthcare devices and has developed over time through specialization and acquisitions. Its corporate headquarters are in San Ramon, California, and it employs more than 15,000 people across roughly 130 countries in Europe, Asia, Africa, and the Americas. That broad geographic footprint is strategically important: it supports a diversified revenue base, gives the company access to a global network of eye-care professionals and fertility clinics, and reduces reliance on any single regional market. ([coopercos.com](https://www.coopercos.com/our-company/?utm_source=openai)) From a competitive standpoint, Cooper Companies is positioned as a focused player in higher-value medical niches rather than as a broad-based medtech conglomerate. In contact lenses, CooperVision competes across daily, monthly, and premium lens categories, while CooperSurgical serves the more specialized needs of obstetrics/gynecology practices and fertility centers. The business model is built around recurring consumption, professional relationships, and product innovation, which can help support customer loyalty and steady demand over time. ([investor.coopercos.com](https://investor.coopercos.com/static-files/78327090-1e4f-43d9-9b08-fac010fe9d65?utm_source=openai)) Its key products and services include soft contact lenses and women’s-health / fertility solutions such as surgical instruments, diagnostic devices, and assisted-reproductive-technology tools. This creates a hybrid profile that combines consumer-like repeat demand with specialty medical devices. For investors, that mix is often attractive because it can provide a balance between growth potential and defensive characteristics. ([coopercos.com](https://www.coopercos.com/our-company/?utm_source=openai)) Recent developments have reinforced that profile. In 2025, CooperCompanies reported quarterly and full-year results highlighting revenue growth, margin improvement, strong free cash flow generation, and ongoing share repurchases. Management also emphasized priorities for 2026 centered on accelerating top-line growth, improving profitability, and increasing cash generation. In practical terms, COO remains a global healthcare name with meaningful exposure to premium contact lenses and fertility/women’s-health demand, listed on the Nasdaq market in the United States. ([investor.coopercos.com](https://investor.coopercos.com/news-releases/news-release-details/coopercompanies-announces-fourth-quarter-and-full-year-2025?utm_source=openai))